Howard University | Department of Psychiatry and Behavioral Sciences (CBOT-OUD Group)

Research site

(Unclaimed)

Location

2041 Georgia Avenue, NW, Suite 5B, Washington, District of Columbia, United States of America

Site insights

Top conditions

Top treatments

Hydroxyurea

Aspirin

Buprenorphine

Emricasan

Estrogen

TAU

elbasvir

Cannabidiol

paritaprevir

Riociguat

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

8 of 56 total trials

A Study of Etavopivat in Adults and Adolescents With Sickle Cell Disease (HIBISCUS)

This clinical trial is a Phase 2/3 study that will evaluate the efficacy and safety of etavopivat and test how well etavopivat works compared to plac...

Enrolling

Sickle Cell Disease

Drug: Placebo Tablets

Drug: Etavopivat Tablets High dose

A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease

This is a multicenter randomized, double-blind, placebo-controlled Phase 2 study designed to evaluate the efficacy, safety, and tolerability of two d...

Enrolling

Early Alzheimer's Disease

Drug: Placebo

Drug: CT1812

AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid

The primary purpose of this study is to determine whether treatment with lecanemab is superior to placebo on change from baseline of the Preclinical...

Enrolling

Preclinical Alzheimer's Disease

Early Preclinical Alzheimer's Disease

Drug: Lecanemab

Drug: Placebo

Development and Evaluation of Computerized Chemosensory-Based Orbitofrontal Networks Training for Treatment of Pain (CBOT-P) (CBOT-P-2)

The overarching goal of this study phase, Phase II component is to perform a randomized clinical trial of the refined Computerized Chemosensory-Based...

Enrolling

Chronic Pain

Low Back Pain

Combination Product: Computerized Chemosensory-Based Orbitofrontal Cortex Training (CBOT)

Combination Product: Computerized Chemosensory-Based Orbitofrontal Cortex Training for Pain

Enhanced Digital-Chemosensory-Based Olfactory Training for Remote Management of Substance Use Disorders (EDITOR)

The overarching goal of this study phase, Phase II component is to implement Enhanced Digital-Chemosensory-Based Olfactory Training for Remote Manage...

Enrolling

Opioid Use Disorder

Substance Use Disorders

Combination Product: CBOT with olfactory stimulants & OFC tasks

Combination Product: EDITOR (CBOT with olfactory stimulants, OFC tasks & remote monitoring of treatment compliance)

Integrating MOUD in African American Community Settings (Better Together)

A multisite effectiveness-implementation study will be conducted in three sites to evaluate interventions to improve engagement and retention in MOUD...

Not yet enrolling

Opioid Use Disorder

Behavioral: BT-MOUD with Buprenorphine

Behavioral: HC-MOUD Only

Repigmentation of Stable Vitiligo Lesions Using Spray-On Skin™ Cells (TONE)

To evaluate repigmentation and quality of life after treatment of stable vitiligo lesions using the RECELL Device.

Active, not recruiting

Vitiligo

Device: RECELL® Autologous Cell Harvesting Device

Research Study Investigating How Well NDec Works in People With Sickle Cell Disease (ASCENT1)

This study examines how well a new, potential medicine called NDec works and is tolerated in people with sickle cell disease. NDec is a combination o...

Enrolling

Sickle Cell Disease

Drug: HU - Hydroxyurea

Drug: Placebo